Steve R. Carchedi is an Independent Director of Sunesis Pharmaceuticals, Inc. Currently, Mr. Carchedi serves as the President, Commercial Operations for Mallinckrodt Specialty Pharmaceuticals, the Pharmaceuticals business of Covidien plc. Mr. Carchedi brings more than 30 years of commercial industry experience focused in Oncology, Neurology, Urology, Endocrinology and Cardiology. Previously, he served as Chief Marketing Officer for General Electric (GE) Healthcare-MDx where he was responsible for worldwide marketing for GE’s Medical Diagnostics business. Prior to joining GE Healthcare, Mr. Carchedi held senior commercial leadership positions at Endo Pharmaceuticals, Enzon Pharmaceuticals and McNeil Specialty Pharmaceuticals, a subsidiary of Johnson & Johnson. Mr. Carchedi also held the position of Global Marketing Leader for Johnson & Johnson Oncology, where he led the worldwide product launch of VELCADE® (bortezomib). Before joining Johnson & Johnson, Mr. Carchedi played a key role in commercializing a number of oncology products, including GEMZAR® (gemcitabine) at Eli Lilly & Company, as well as TAXOL® (paclitaxel) and PARAPLATIN® (carboplatin) at Bristol Myers Squibb. In addition to his industry experience, Mr. Carchedi currently serves on the Board of Directors of BioNumerick Pharmaceuticals, on the Strategic Advisory Board for PCAsso Diagnostics LLC, and as Co-Chair of BioNJ’s Personalized Medicine & Diagnostics Committee. Mr. Carchedi received a B.S. in Marketing from West Chester University and an MBA in Marketing from Drexel University.
Steve's mailing address filed with the SEC is SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BOULEVARD, STE. 400, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 19 years, insiders at Sunesis Pharmaceuticals Inc have traded over 89,557,714$ worth of Sunesis Pharmaceuticals Inc stock and bought 191,253,594 units worth 84,730,221$ . The most active insiders traders include Forest Baskett、Scott D Sandell、Peter J Barris. On average, Sunesis Pharmaceuticals Inc executives and independent directors trade stock every 67 days with the average trade being worth of 14,060,191$. The most recent stock trade was executed by Tina Gullotta on 29 May 2020, trading 6,000 units of SNSS stock currently worth 1,980$.
Sunesis Pharmaceuticals Inc executives and other stock owners filed with the SEC include: